Skip to main content
SpringerLink
Log in

Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Ecotropic virus integration site-1 (EVI1) is frequently expressed in patients with acute myeloid leukemia (AML). Many studies have reported the potential poor prognostic impact of EVI1 higher expression (EVI1H) in the AML patients; however, the conclusions previously reported have not been fully assessed and are still controversial. Therefore, we performed a meta-analysis to evaluate the prognostic significance of EVI1H in patients with AML. The primary endpoint was overall survival (OS), and the event-free survival (EFS) was selected as the secondary endpoint. We extracted the hazard ratio (HR) and their 95% confidence interval (CI) for the OS and EFS from the multivariate COX proportional hazard models. A total of 4767 AML patients from 11 studies up to 23 February 2019 were subjected to our meta-analysis. Pooled HRs suggested that EVI1H had an adverse impact on OS (HR = 1.52, 95%CI 1.24–1.86) and EFS (HR = 1.41, 95%CI 1.14–1.74) in AML patients. EVI1H was also associated with a shorter OS (HR = 1.73, 95%CI 1.43–2.11) and EFS (HR = 1.17, 95%CI 1.05–1.31) in AML patients with the intermediate cytogenetic risk (ICR) according to the National Comprehensive Cancer Network (NCCN), European leukemia network (ELN), or International System for Human Cytogenetic Nomenclature (ISCN). Furthermore, EVI1H appeared to be a poor prognosis indicator in patients with normal cytogenetics (NC) (HR for OS:2.01, 95%CI 1.32–3.05; HR for EFS 1.54, 95%CI 1.09–2.17) and young patients (HR for OS 1.30, 95%CI 1.09–1.55), respectively. This meta-analysis indicates EVI1H has an independent and significantly adverse prognostic impact on AML patients in the entire population, and this conclusion same applies to some subgroups like AML patients with ICR, NC, and young AML patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Short NJ, Rytting ME, Cortes JE (2018) Acute myeloid leukaemia. Lancet (London, England) 392(10147):593–606. https://doi.org/10.1016/s0140-6736(18)31041-9

    Article  Google Scholar 

  2. Theilgaard-Monch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A, Morgan M, Porse B, Tagliafico E, Zwaan CM, Wainscoat J, Van den Heuvel-Eibrink MM, Mills K, Bullinger L (2011) Gene expression profiling in MDS and AML: potential and future avenues. Leukemia 25(6):909–920. https://doi.org/10.1038/leu.2011.48

    Article  CAS  PubMed  Google Scholar 

  3. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Lowenberg B, Bloomfield CD (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447. https://doi.org/10.1182/blood-2016-08-733196

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Marcucci G, Haferlach T, Dohner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol : Off J Am Soc Clin Oncol 29(5):475–486. https://doi.org/10.1200/jco.2010.30.2554

    Article  CAS  Google Scholar 

  5. Kataoka K, Kurokawa M (2012) Ecotropic viral integration site 1, stem cell self-renewal and leukemogenesis. Cancer Sci 103(8):1371–1377. https://doi.org/10.1111/j.1349-7006.2012.02303.x

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Mucenski ML, Taylor BA, Ihle JN, Hartley JW, Morse HC 3rd, Jenkins NA, Copeland NG (1988) Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol 8(1):301–308. https://doi.org/10.1128/mcb.8.1.301

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Morishita K, Parker DS, Mucenski ML, Jenkins NA, Copeland NG, Ihle JN (1988) Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell 54(6):831–840

    Article  CAS  PubMed  Google Scholar 

  8. Goyama S, Kurokawa M (2009) Pathogenetic significance of ecotropic viral integration site-1 in hematological malignancies. Cancer Sci 100(6):990–995. https://doi.org/10.1111/j.1349-7006.2009.01152.x

    Article  CAS  PubMed  Google Scholar 

  9. Hinai AA, Valk PJ (2016) Review: aberrant EVI1 expression in acute myeloid leukaemia. Br J Haematol 172(6):870–878. https://doi.org/10.1111/bjh.13898

    Article  CAS  PubMed  Google Scholar 

  10. Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111(8):4329–4337. https://doi.org/10.1182/blood-2007-10-119230

    Article  CAS  PubMed  Google Scholar 

  11. Barjesteh van Waalwijk van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Lowenberg B, Delwel R (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101(3):837–845. https://doi.org/10.1182/blood-2002-05-1459

    Article  CAS  PubMed  Google Scholar 

  12. Groschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kuhn MW, Eiwen K, Erpelinck C, Havermans M, Lubbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Lowenberg B, Dohner K, Dohner H, Delwel R (2013) Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian acute myeloid leukemia study group and the Dutch-Belgian-Swiss HOVON/SAKK cooperative group. J Clin Oncol : Off J Am Soc Clin Oncol 31(1):95–103. https://doi.org/10.1200/jco.2011.41.5505

    Article  Google Scholar 

  13. Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Lowenberg B, Valk PJ (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118(4):1069–1076. https://doi.org/10.1182/blood-2011-02-334748

    Article  CAS  PubMed  Google Scholar 

  14. Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lubbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Dohner H, Lowenberg B, Dohner K, Delwel R (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol: Off J Am Soc Clin Oncol 28(12):2101–2107. https://doi.org/10.1200/jco.2009.26.0646

    Article  Google Scholar 

  15. Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (2008) Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes, Chromosomes & Cancer 47(4):288–298. https://doi.org/10.1002/gcc.20532

    Article  CAS  Google Scholar 

  16. Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Bejar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gomez-Casares MT, Hernandez-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD (2011) Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 96(10):1448–1456. https://doi.org/10.3324/haematol.2011.040535

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, Zhao XS, Shi HX, Liu YR, Jiang H, Huang XJ, Jiang Q (2018) High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit : Int Med J Exp Clin Res 24:758–767

    Article  CAS  Google Scholar 

  18. Yamato G, Yamaguchi H, Handa H, Shiba N, Kawamura M, Wakita S, Inokuchi K, Hara Y, Ohki K, Okubo J, Park MJ, Sotomatsu M, Arakawa H, Hayashi Y (2017) Clinical features and prognostic impact of PRDM16 expression in adult acute myeloid leukemia. Genes, Chromosomes Cancer 56(11):800–809. https://doi.org/10.1002/gcc.22483

    Article  CAS  PubMed  Google Scholar 

  19. Langabeer SE, Rogers JR, Harrison G, Wheatley K, Walker H, Bain BJ, Burnett AK, Goldstone AH, Linch DC, Grimwade D (2001) EVI1 expression in acute myeloid leukaemia. Br J Haematol 112(1):208–211

    Article  CAS  PubMed  Google Scholar 

  20. Balgobind BV, Lugthart S, Hollink IH, Arentsen-Peters ST, van Wering ER, de Graaf SS, Reinhardt D, Creutzig U, Kaspers GJ, de Bont ES, Stary J, Trka J, Zimmermann M, Beverloo HB, Pieters R, Delwel R, Zwaan CM, van den Heuvel-Eibrink MM (2010) EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia 24 (5):942–949. doi:https://doi.org/10.1038/leu.2010.47

    Article  CAS  PubMed  Google Scholar 

  21. Wells GA, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available from: http:// www.ohri.ca/programs/clinical_epidemiology/oxford.asp

  22. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ (Clinical research ed) 327(7414):557–560. https://doi.org/10.1136/bmj.327.7414.557

    Article  Google Scholar 

  23. Begg CB, Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. Biometrics 50(4):1088–1101

    Article  CAS  PubMed  Google Scholar 

  24. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res) 315(7109):629–634. https://doi.org/10.1136/bmj.315.7109.629

    Article  CAS  Google Scholar 

  25. Zhu YM, Wang PP, Huang JY, Chen YS, Chen B, Dai YJ, Yan H, Hu Y, Cheng WY, Ma TT, Chen SJ, Shen Y (2017) Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance. J Transl Med 15(1):178. https://doi.org/10.1186/s12967-017-1279-4

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Bou Samra E, Klein B, Commes T, Moreaux J (2012) Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget 3(8):824–832. https://doi.org/10.18632/oncotarget.571

    Article  PubMed  PubMed Central  Google Scholar 

  27. Goyama S, Yamamoto G, Shimabe M, Sato T, Ichikawa M, Ogawa S, Chiba S, Kurokawa M (2008) Evi-1 is a critical regulator for hematopoietic stem cells and transformed leukemic cells. Cell Stem Cell 3(2):207–220. https://doi.org/10.1016/j.stem.2008.06.002

    Article  CAS  PubMed  Google Scholar 

  28. Wieser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396(2):346–357. https://doi.org/10.1016/j.gene.2007.04.012

    Article  CAS  PubMed  Google Scholar 

  29. Yoshimi A, Goyama S, Watanabe-Okochi N, Yoshiki Y, Nannya Y, Nitta E, Arai S, Sato T, Shimabe M, Nakagawa M, Imai Y, Kitamura T, Kurokawa M (2011) Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. Blood 117(13):3617–3628. https://doi.org/10.1182/blood-2009-12-261602

    Article  CAS  PubMed  Google Scholar 

  30. Shimabe M, Goyama S, Watanabe-Okochi N, Yoshimi A, Ichikawa M, Imai Y, Kurokawa M (2009) Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. Oncogene 28(49):4364–4374. https://doi.org/10.1038/onc.2009.288

    Article  CAS  PubMed  Google Scholar 

  31. Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24(11):1976–1987. https://doi.org/10.1038/sj.emboj.7600679

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Glass C, Wuertzer C, Cui X, Bi Y, Davuluri R, Xiao YY, Wilson M, Owens K, Zhang Y, Perkins A (2013) Global identification of EVI1 target genes in acute myeloid leukemia. PLoS One 8(6):e67134. https://doi.org/10.1371/journal.pone.0067134

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The work was supported by the Foundation of the Science & Technology Department of Sichuan Province (NO. 2015SZ0234-5) and Foundation of Chengdu Science and Technology Bureau (NO. 2016-HM01-00001-SF).

Author information

Authors and Affiliations

  1. Department of Hematology, West China Hospital, Sichuan University, No.37 GuoXue Xiang, Chengdu, 610041, Sichuan Province, China

    Xia Wu, Huifang Wang, Jili Deng, Xue Zheng, Yantao Ling & Yuping Gong

Authors
  1. Xia Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huifang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jili Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xue Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yantao Ling
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuping Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: Xia Wu, Yuping Gong.

Studies screen: Xia Wu, Jili Deng, Huifang Wang.

Collection Of data: Xia Wu, Jili Deng, Huifang Wang.

Analysis of data: Xia Wu, Yantao Ling, Xue Zheng.

Funding acquisition: Yuping Gong.

Methodology: Xia Wu, Xue Zheng, Yantao Ling.

Writing-original draft: Xia Wu, Yuping Gong.

Writing-review & editing: Xia Wu, Yuping Gong.

Corresponding author

Correspondence to Yuping Gong.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethics statement

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 1.51 mb)

ESM 2

(PDF 89.3 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, X., Wang, H., Deng, J. et al. Prognostic significance of the EVI1 gene expression in patients with acute myeloid leukemia: a meta-analysis. Ann Hematol 98, 2485–2496 (2019). https://doi.org/10.1007/s00277-019-03774-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-019-03774-z

Keywords

Search

Navigation